Click a keyword to view all the abstracts on this site tagged with that keyword.
- Doppler ultrasound
- Doppler ultrasound and large vessel vasculitis
- Doppler ultrasound and psoriatic arthritis
- Doppler ultrasound and Risk Prediction
- Doppler ultrasound and salivary gland
- Doppler ultrasound and Shared Epitope
- Doppler ultrasound and Synovial Immune Biology
- dorsal root ganglia
- doube negative T cell
- Doxycycline
- doxycycline and inflammation
- DQB1*0601
- drug
- drug induced vasculitis and small vessel vasculitis
- drug interactions
- drug interactions and drug therapy
- drug interactions and fibromyalgia
- drug interactions and pain management
- drug interactions and rheumatoid arthritis (RA)
- Drug interactions and spondylarthropathy
- drug repurposing
- drug safety
- drug safety and clinical trials
- drug safety and drug persistence
- Drug safety and health care cost
- drug safety and health literacy
- drug safety and infection
- drug safety and registries
- drug safety and rheumatoid arthritis
- drug safety and rheumatoid arthritis (RA)
- drug safety and safety
- drug safety and tumor necrosis factor (TNF)
- drug safety monitoring
- drug safety monitoring and pregnancy
- drug safety monitoring and quality measures
- drug safety monitoring and randomized trials
- drug safety monitoring and repository corticotropin injection
- drug survival
- drug therapy
- drug therapy and clinical trials
- drug therapy and drug safety
- drug therapy and drug treatment
- drug therapy and fibromyalgia
- drug therapy and fracture risk
- drug therapy and gout
- drug therapy and iron metabolism
- drug therapy and methotrexate (MTX)
- drug therapy and osteoporosis
- drug therapy and pharmacotherapy
- drug therapy and proteinuria
- drug therapy and psoriatic arthritis
- drug therapy and rheumatoid arthritis (RA)
- Drug therapy and systemic sclerosis
- drug therapy and transcriptional regulation
- drug therapy and treatment options
- Drug toxicity
- drug toxicity and hydroxychloroquine
- drug toxicity and inflammatory arthritis
- Drug toxicity and methotrexate (MTX)
- drug toxicity and rheumatoid arthritis (RA)
- drug toxicity and vasculitis
- drug treatment
- drug treatment and biologic drugs
- drug treatment and clinical trials
- drug treatment and imaging techniques
- drug treatment and inflammation
- drug treatment and medication
- drug treatment and mouse model
- drug treatment and osteoarthritis
- drug treatment and outcomes
- drug treatment and pharmacokinetics
- drug treatment and rheumatic disease
- drug treatment and rheumatoid arthritis (RA)
- drug treatment and safety
- drug treatment and steroid sparing
- Drug-Drug Interference
- Drug-Sparing Effect
- dry eyes
- dry eyes and genomics
- dry eyes and measure
- dry eyes and Rheumatoid Factor
- DsDNA antibody
- Dual energy x-ray absorptiometry (DEXA)
- dual energy x-ray absorptiometry (DEXA) and bone health
- dual energy x-ray absorptiometry (DEXA) and diagnosis
- dual energy x-ray absorptiometry (DEXA) and Femur Fractures
- dual energy x-ray absorptiometry (DEXA) and juvenile SLE
- dual energy x-ray absorptiometry (DEXA) and osteoarthritis
- Dual energy x-ray absorptiometry (DEXA) and osteoporosis
- dual energy x-ray absorptiometry (DEXA) and parathyroid hormone
- dual energy x-ray absorptiometry (DEXA) and positron emission tomography (PET)
- dual energy x-ray absorptiometry (DEXA) and psoriatic arthritis
- dual energy x-ray absorptiometry (DEXA) and rheumatoid arthritis (RA)
- dual energy x-ray absorptiometry (DEXA) and spondylarthritis
- dual energy x-ray absorptiometry (DEXA) and systemic lupus erythematosus (SLE)
- dual energy x-ray absorptiometry (DEXA) and treatment
- dual energy x-ray absorptiometry (DEXA) and ultrasound
- dual femur
- Dual-energy computed tomography
- dual-energy CT and ultrasound
- Duloxetine
- DXA
- DXA and osteoporosis
- Dysmotility
- Dyspnea
- Dyspnea and systemic sclerosis
- e health
- E-Genes and Ancestry
- Ear, Nose and Throat Involvement
- early diagnosis
- early retirement and socioeconomic factors
- Early Rheumatoid Arthritis
- Early Rheumatoid Arthritis and abatacept
- Early Rheumatoid Arthritis and anti-CCP antibodies
- Early Rheumatoid Arthritis and anti-citrullinated protein/peptide antibodies (ACPA)
- Early Rheumatoid Arthritis and arthroscopy
- Early Rheumatoid Arthritis and B cells
- Early Rheumatoid Arthritis and biomarkers
- Early Rheumatoid Arthritis and cardiovascular disease
- Early Rheumatoid Arthritis and cartilage
- Early Rheumatoid Arthritis and classification criteria
- Early Rheumatoid Arthritis and comorbidity
- Early Rheumatoid Arthritis and depression
- Early Rheumatoid Arthritis and diabetes
- Early Rheumatoid Arthritis and diagnosis
- Early Rheumatoid Arthritis and fracture risk
- Early Rheumatoid Arthritis and galectin
- Early Rheumatoid Arthritis and Gene Expression
- Early Rheumatoid Arthritis and glucocorticoids
- Early Rheumatoid Arthritis and inflammation
- Early Rheumatoid Arthritis and interferons
- Early Rheumatoid Arthritis and lung
- Early Rheumatoid Arthritis and Lung Disease
- Early Rheumatoid Arthritis and methotrexate (MTX)
- Early Rheumatoid Arthritis and outcome measures
- Early Rheumatoid Arthritis and patient outcomes
- Early Rheumatoid Arthritis and polyunsaturated fatty acid
- Early Rheumatoid Arthritis and prediction model
- Early Rheumatoid Arthritis and quality of life
- Early Rheumatoid Arthritis and Rapid Radiograhic Progression
- Early Rheumatoid Arthritis and remission
- Early Rheumatoid Arthritis and rheumatoid arthritis (RA)
- Early Rheumatoid Arthritis and tendonitis/bursitis
- Early Rheumatoid Arthritis and tocilizumab
- Early Rheumatoid Arthritis and treatment
- Early Rheumatoid Arthritis and Triage
- Early Rheumatoid Arthritis and ultrasonography
- Early Rheumatoid Arthritis and Work Disability
- Early treatment and remission induction
- Ebola virus
- EBV
- ECLIPSE
- Economics
- economics and education
- economics and etanercept
- Economics and gout
- economics and healthcare policy
- economics and inflammatory arthritis
- Economics and juvenile arthritis
- economics and non-radiographic
- economics and patient preferences
- Economics and psoriatic arthritis
- economics and quality improvement
- economics and quality of life
- economics and rheumatoid arthritis
- economics and rheumatoid arthritis (RA)
- economics and risk
- Economics and systemic lupus erythematosus (SLE)
- economics and tocilizumab
- economics and treatment
- ectonucleotidase
- Edema
- Education
- education and educational research
- education and epidemiologic methods
- education and fibromyalgia
- Education and gout
- education and health disparities
- Education and joint procedures
- education and knowledge
- Education and medical education
- education and morbidity and mortality
- education and musculoskeletal disorders
- Education and online resources
- education and professional development
- education and race/ethnicity
- education and rheumatic education
- education and rheumatoid arthritis (RA)
- education and social media
- education and socioeconomic factors
- education and technology
- education and trainee
- Education and ultrasonography
- Education and ultrasound
- education, medical
- education, patient
- educational innovation
- educational innovation and clinical skills
- educational innovation and educational research
- educational innovation and evaluation